Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 10/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20710319 | 0.85 | RIPK1 (0.63) | RIPK1L3MBTL1ALDH1A1 | |
| SCHEMBL20710310 | 0.85 | RIPK1 (0.63) | RIPK1L3MBTL1ALDH1A1 | |
| SCHEMBL17881980 | 0.85 | RIPK1 (0.63) | RIPK1L3MBTL1ALDH1A1 | |
| SCHEMBL17881960 | 0.81 | RIPK1 (0.71) | RIPK1DRD4KCNQ2SCD5ALDH1A1 | |
| SCHEMBL17881986 | 0.79 | RIPK1 (0.80) | RIPK1SCD5PDE5A | |
| SCHEMBL20710358 | 0.77 | RIPK1 (0.65) | RIPK1L3MBTL1 | |
| SCHEMBL17881972 | 0.69 | RIPK1 (0.69) | RIPK1SCD5 | |
| SCHEMBL18997543 | 0.69 | RIPK1 (0.52) | RIPK1KCNQ2SCD5TDP1LIPE | |
| SCHEMBL28167683 | 0.69 | RIPK1 (0.58) | RIPK1DRD4PDE5A | |
| SCHEMBL19002800 | 0.67 | DRD3 (0.48) | SCD5TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10555920-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-02-11 | — | — | US | disclosed |
| US-20190038578-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190038578-A1 | Necrosis Inhibitors | RIPK3, RIPK1, RIPK4 | RIPK1 2/4885DRD4 4346/4885L3MBTL1 3530/4885 |
| US-10555920-B2 | Necrosis inhibitors | RIPK3, RIPK1, RIPK4 | RIPK1 2/4885DRD4 4346/4885L3MBTL1 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.